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ABSTRACT
Background and the purpose of the study: Technetium-99m is the major radionuclide used in 
the world and mainly is provided by fission product. However extensive research has been 
conducted on the use of accelerators for production of  99mTc. This investigation reports the 
production  of  99mTc  radioisotope  using  cyclotrons  and  the  preparation,  quality  control  and 
biodistribution studies of four major Tc-radiopharmaceuticals. 
Methods: The high purity molybdenum natural target (130 mg/cm2) was irradiated in a Cyclone 
30 accelerator using 160 µA of 25 MeV proton beam energy for 1000 µA-h. After dissolution, 
the technetium radionuclides were extracted using methyl ethyl ketone (MEK) followed by 
preparation of Tc-MIBI, Tc-DTPA, Tc-DMSA and Tc-phytate as radiopharmaceutical samples. 
Results: The results of quality controls and animal biodistribution studies showed successful 
production  of  Tc  radionuclides  (including  99mTc)  in  the  bombarded  target  and  subsequent 
labelling of the kit with Tc. 
Conclusion: The developed high power Mo target if constructed using enriched 100Mo, could be 
a practical method for large-scale production of 99mTc and promising as an alternative to fission 
product 99Mo-99mTc generators for local applications near cyclotron facilities.
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INTRODUCTION
99mTc  for  the  use  in  nuclear  medicine  has  been 
produced by indirect method by means of nuclear 
reactors  (99Mo-  99mTc  generator)  where  99Mo  is  a 
fission  product.  99mTc  could  also  can  be  produced 
directly using proton bombardment via 100Mo (p, 2n) 
99mTc nuclear reaction (1).
 One of the main advantages of the direct production 
of  99mTc using cyclotrons is its low environmental 
hazards  and  less  waste  management  difficulties 
relative  to  fission-product  method,  however,  due 
to relatively short half-life of  99mTc (6.02 hrs), the 
direct  production  method  could  only  be  used  for 
local applications.
Many  research  groups  have  studied  small  scale 
production  of  99mTc  by  low  current  proton  beam 
bombardment of molybdenum targets in accelerators 
using  direct  and  indirect  methods  (2-4).  In  most 
cases, molybdenum targets for  99mTc production in 
accelerators  have  been  produced  using  thin  layer 
coating,  metallic  foil  preparation,  molybdenum 
oxide precipitation and pills made from molybdenum 
powder and/or its compounds (5), but due to the low 
heat transfer characteristics of these targets, which 
cannot  withstand  high  currents,  the  production 
of  99mTc in large scale have not yet been achieved 
(6). Successful thick metallic natural molybdenum 
target  with  high  thermal  conductivity  to  produce 
99mTc using high current proton beams (7) has been 
reported. It should also be mentioned that the use of 
Mo target enriched in 100Mo instead of natural Mo 
and the choice of the suitable proton energy, and 
high current will result in much higher activity of 
99mTc and very low amount of impure by-products 
(2). 
In  order  to  investigate  the  performance  of  the 
designed  high  power  molybdenum  target,  proton 
bombardment of the constructed natural molybdenum 
target  was  conducted  at  160  microamperes  (the 
highest accessible current in cyclotron under study 
at the time of experiments). All the above reported 
investigations have been carried out to find out the 
efficacy of our designed and constructed high power 
Mo target to produce  99mTc on a large scale with 
the capability of its labelling with Tc kits (Fig. 1.). 
After targetry studies, fabrication and production of 
187Tc-99m radiopharmaceutical production in cyclotrons 188
Tc radioisotopes, the sterile final TcO4
- solution was 
used  in  radiopharmaceutical  preparation  followed 
by common quality control tests and biodistribution 
studies in wild-type rats. 
MATERIAL AND METHODS
Instant  thin  layer  chromatography  (ITLC)  was 
performed by counting Whatman paper using a thin 
layer  chromatography  scanner,  Bioscan  AR2000, 
Bioscan Europe Ltd. (France). All calculations and 
RTLC counting were based on 99mTc 140.5 keV peak. 
Natural  molybdenum  with  high  chemical  purity 
(more than 99%) was obtained from Merck Chemical 
Co. (Germany). Tc cold kits were purchased from 
Kavoshyar Co. Tehran, Iran. 
Targetry
The  detailed  targetry  of  the  Mo  target  has  been 
reported previously (7). Briefly, natural molybdenum 
isotopes with an approximate thickness of 130 mg/cm2 
(about 130 µm ) were coated as metallic layer on 
copper backing on an area of 20.5 cm2 using thermal 
spray coating method (8). The prepared target was 
irradiated  by  160µA  protons  beam  of  25  MeV 
for 1000µA-h in a Cyclone30). At this angle, the 
effective thickness of the target is about 10 times of 
the actual thickness (i.e. 1300mg/cm2 approx.).
Radionuclides assays
The activities of various technetium radionuclides 
produced in the target were measured 12 hrs after 
EOB  using  gamma  spectroscopy  system  with 
an  HPGe  detector  of  38.5%  relative  efficiency. 
Calibration of energy and efficiency of this detector 
was achieved by a mixed-radionuclide (133Ba, 241Am, 
137Cs, 60Co and 152Eu) reference source. The detector 
was coupled to an MCA Plug-In Card, and the card 
was connected to an IBM-compatible PC-AT. 
Extraction  of 
−
4 TcO in  normal  saline  for  kit 
radioradiolabeling
The molybdenum target layer was rapidly dissolved 
by the use of a mixture of warm HNO3 and HCl, 
(6.7, and 13.3 ml, respectively). After dissolution, 
the pH. of the mixture was changed to basic by 
the  addition  of  NaOH  and  the  radioactive TcO4 
was extracted into an equivolume of methyl ethyl 
ketone (MEK) (9). After four solvent extractions, 
the technetium bearing MEK fraction was blown 
dry in a nitrogen stream at 100°C and taken up in 
1ml  of  0.9%  physiological  saline.  This  activity 
(pH=7)  proved  to  be  >99% 
−
4 TcO as  shown  by 
thin-layer  chromatography  (TLC)  (silica  gel, 
MEK Rf=0.9). The 
−
4 TcO solution was next passed 
through a sterile, 0.22 µm filter (Millipore, Millex 
GV) prior to introduction into any commercial kit 
preparation.
Chemical purity control
The presence of Cu2+, Zn2+ and MoO4
2- ions were detected 
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in the final TcO4 solution using simple colorimetric tests. 
The presence of zinc and copper  cations was detected 
by visible colorimetric assays (10, 11). 
For MoO4
2- ion detection, two instant colorimetric 
methods  were  developed  through  some 
modifications  in  the  reported  method  (12). 
Typically, equal volumes of final pharmaceutical 
Solution,  10%  ammonium  thiocyanate  solutions 
and  5%  stannous  chloride  (solution  in  diluted. 
HCl) were mixed. The yellow coloration as a result 
of  (NH4)3[Mo(CNS)6]  water  soluble  complex 
formation appeared by using blank and standard 
samples (limit of detection 0.1 ppm). 
Preparation of [Tc]-radiopharmaceuticals
All kits were labelled at room temperature except 
MIBI. Typically, 20-30 mCi (about 1 GBq) of  TcO4  
prepared in 1ml of 0.9% physiological saline was 
introduced into the commercial related kit, shaken 
and kept at room temperature for 30 min. At the end 
of labelling, radiochemical purities were verified by 
both standard TLCs (Whatman No.2, mobile phases 
of saline and silica gel using MEK as eluent).
Biodistribution of Tc-radiopharmaceuticals in wild-
type rats
Each Tc-tracer was administered to three separate 
normal rat groups. A volume (50 µl) of Tc-tracer 
solutions  containing  80±2  µCi  radioactivity  was 
injected intravenously to rats via their tail veins. 
The animals were sacrificed at exact time intervals 
(30, 60 and 120 min), and the ID/g% of different 
organs was determined as percentage of injected 
dose (based on the area under the curve of 140.5 
keV  99mTc  gamma  line)  per  gram  by  gamma 
spectroscopy using HPGe detector.
DISCUSSION
Production
Extraction  of  technetium  radionuclides  were 
successfully  performed  from  the  bombarded 
molybdenum target at the specific pH with the lowest 
impurities  and  timely  manner.  Due  to  the  use  of 
natural Mo target, several technetium radioisotopes 
were produced as by-products of 99mTc such as 99mTc 
(6.02 hrs),  96Tc (104.4 hrs),  95mTc (1464 hrs),  95Tc 
(20.0 hrs),  94Tc (4.8 hrs) and  93Tc (2.75 hrs). The 
chemical purity of the final solution was checked by 
colorimetric method. The data for 5 different runs 
are summarized in Table 1.
Radionuclidic studies
The  γ-ray  spectrum  of  the  diluted  sample  of  Tc 
radionuclides 12 hrs after the end of bombardment 
(EOB) has been reported previously (7).
According  to  the  results  of  investigations  carried 
out  by  Lagunas-Solar  (2),  it  is  anticipated  that 
using enriched  100Mo instead of  natMo and proton 
beam of about 1mA, about 100 Ci of  99mTc could 
be produced. However, 100% enriched 100Mo is not 
available, so reactions leading to the formation of 
radionuclide impurities such as  94Tc,  95Tc and  96Tc 
are of high concern for the production of high purity 
99mTc from enriched 100Mo targets. Recently, Cross-
sections for the proton induced reactions on natural 
molybdenum  was  measured  in  the  proton  energy 
range 8.4-37.1 MeV in order to monitor the presence 
of other technetium nuclides better (13).
Radiolabeling procedures
After extraction of 
−
4 TcO in normal saline for kit 
radioradiolabeling, preparation of [99mTc]-complexes 
as model radiolabeled kits was investigated. Four 
major Tc-cold kits were considered as models for 
the feasibility study of final radionuclide labelling 
performance.
At  the  end  of  labelling,  radiochemical  purity  in 
excess of 97% was shown by both standard TLCs 
(Table 2).
Biodistribution studies
Figure  2.  shows  the  biodistribution  of  Tc-DTPA 
as  a  kidney  perfusion  agent,  this  water  soluble 
complex is washed out from the kidneys and finally 
accumulates in bladder especially after 60 min post-
injection.  A  small  portion  of  the  activity  is  also 
present in the stomach and lung. Thyroid uptake is 
negligible (about 0.01%), demonstrating the absence 
of free pertechnetate. 
Figure 3 shows the biodistribution of Tc-MIBI in the 
rat organs, being used mostly as a tracer in SPECT 
cardiology. MIBI was selected as another model kit. 
As expected in 30 min post injection the major target 
organ  is  myocardium,  while  kidney,  faeces  and 
stomach are also major accumulation sites. Again, 
thyroid uptake is low in all time intervals. 
Another  Tc-kit  used  in  this  study  was  phytate,  a 
poly  phosphate  compound,  easily  radiolabled  by 
Tc.  The  final  complex  is  mainly  accumulated  in 
reticuloendothelial  system,  including  the  liver, 
a  major  site  of  accumulation,  and  then  with  less 
contents  in  the  spleen  and  the  lung  respectively. 
Negligible thyroid uptake is observed (Fig4.).
Finally  Tc-DMSA  was  another  selective  kidney 
tracer which was radiolabeled in this study in order 
to demonstrate the purity and labelling capacity of 
Tc produced in this work. Figure 5. demonstrates 
that the complex is washed out from the kidneys 
and  finally  accumulates  in  bladder  specially  after 
60 min post-injection. Thyroid uptake is negligible 
(about 0.02%), demonstrating the absence of free 
pertechnetate.
The results of measurements are in agreement with the 
expected time behaviour of the kit in different organs 
(14,  15),  which  shows  the  successful  production  of 
Tc radionuclides (including  99mTc) in the bombarded 
target  and  subsequent  labelling  of  the  kit  with  Tc. Tc-99m radiopharmaceutical production in cyclotrons 190
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uptake is low in all time intervals. 
Fig 3. Calculated ID/gr% of Tc-MIBI (80µCi), 30-120 minutes post I.V. injection 
in wild-type rat organs. 
Another Tc-kit used in this study was phytate, a poly phosphate compound, easily 
radiolabled by Tc. The final complex is mainly accumulated in reticuloendothelial 
system,  including  the  liver,  a  major  site  of  accumulation,  and  then  with  less 
contents  in  the  spleen  and  the  lung  respectively.  Negligible  thyroid  uptake  is 
observed (Fig4.). 
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Compound  Labelling 
time (min) 
Radiochemical 
purity (%) 
Rf in 
MEK 
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(ºC)
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fig 4. Calculated ID/gr% of Tc-phytate (80µCi), 30-120 minutes post I.V. 
injection in wild-type rat organs.
Finally Tc-DMSA was another selective kidney tracer which was radiolabeled in 
this study in order to demonstrate the purity and labelling capacity of Tc produced 
in  this  work.  Figure  5.  demonstrates  that  the  complex  is  washed  out  from  the 
kidneys and finally accumulates in bladder specially after 60 min post-injection. 
Thyroid uptake  is  negligible  (about  0.02%),  demonstrating  the  absence  of  free 
pertechnetate. 
Fig 5. Calculated ID/gr% of Tc-DMSA (80µCi), 30-120 minutes post I.V. 
injection in wild-type rat organs. 
 The results of measurements are in agreement with the expected time behaviour 
of the kit in different organs (14,15), which shows the successful production of Tc 
radionuclides (including 
99mTc) in the bombarded target and subsequent labelling 
of the kit with Tc. The radiopharmaceutical were administered to normal rats and 
showed acceptable  ID/g % as a Tc-radiopharmaceutical. This observations show 
the production of Tc radionuclides (including 
99mTc) and subsequent successful 
labelling of the kit. It is also anticipated that the developed coating method for 
The  radiopharmaceutical  were  administered  to 
normal rats and showed acceptable  ID/g % as a Tc-
radiopharmaceutical.  This  observations  show  the 
production of Tc radionuclides (including  99mTc) and 
subsequent  successful  labelling  of  the  kit.  It  is  also 
anticipated  that  the  developed  coating  method  for 
production of high power Mo targets using enriched 
100Mo instead of natural Mo, is capable to produce about 
100 Ci of 99mTc using proton beam of about 1mA. 
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Ion species Reagent Color Run 1 Run 2 Run 3 Run 4
Cu2+ Dithisone Pinkish <1 ppm <0.5 ppm <1 ppm <0.5 ppm
MoO4 
2- NH4SCN, Sn2+ Yellow <0.2 ppm <0.1 ppm <0.1 ppm <0.1 ppm
Zn2+ Dithisone Purple <0.2 ppm <0.1 ppm <0.2 ppm <0.3 ppm
Table 1. Colorimetric data for 4 different sample runs.
solvent TcO4 Tc-radiopharmaceutical colloids
MEK 0.9 0.2-0.1 0.0-0.1
Normal saline 0.8 0.1 0.05
saline/acetone 0.5 0.0 0.05
Table 2. ITLC systems used for the radiochemical purity of the Tc-complexes on Whatman No. 2 papers.
Compound Labelling time (min) Radiochemical purity (%) Rf in MEK Temperature (ºC)
Tc-DMSA 5 97±2 0.1 25
Tc-MIBI 20 94±3 0.05 90
Tc-DTPA 5 98±1 0.0 25
Tc-Phytate 10 96±2 0.1 25
Table 3. Radioradiolabeling properties of four Tc-kits used in this study.Tc-99m radiopharmaceutical production in cyclotrons 192
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